Last reviewed · How we verify
Janssen Cilag S.A.S. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Epo-alpha | Epo-alpha | phase 3 | Erythropoiesis-stimulating agent (ESA) | Erythropoietin receptor (EPOR) | Hematology/Oncology |
Therapeutic area mix
- Hematology/Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Amgen · 1 shared drug class
- Anemia Working Group Romania · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
- Barts & The London NHS Trust · 1 shared drug class
- Bio Sidus SA · 1 shared drug class
- Affymax · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Janssen Cilag S.A.S.:
- Janssen Cilag S.A.S. pipeline updates — RSS
- Janssen Cilag S.A.S. pipeline updates — Atom
- Janssen Cilag S.A.S. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Janssen Cilag S.A.S. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-s-a-s. Accessed 2026-05-17.